Previous 10 |
Athersys, Inc. (ATHX) Q4 2018 Results Earnings Conference Call March 14, 2019, 04:30 PM ET Company Participants Laura Campbell - Senior Vice President, Finance Gil Van Bokkelen - Chairman and Chief Executive Officer BJ Lehmann - President and Chief Operating Officer Conference...
Substantial progress over the year, advancing programs and expanding collaboration with HEALIOS K.K. Management to host conference call at 4:30 PM EST today CLEVELAND, March 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its fourth quarter 2018 an...
Athersys (NASDAQ: ATHX ): Q4 GAAP EPS of -$0.08 in-line. More news on: Athersys, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
CLEVELAND, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, March 14, 2019, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gi...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...